Clinical Trials Logo

Malignant Solid Tumor clinical trials

View clinical trials related to Malignant Solid Tumor.

Filter by:

NCT ID: NCT01606748 Completed - Clinical trials for Malignant Solid Tumor

A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin

Start date: August 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the pharmacokinetics (PK) of necitumumab in combination with gemcitabine-cisplatin in participants with advanced malignant solid tumors and to assess the potential for drug-drug interactions between necitumumab and gemcitabine-cisplatin.

NCT ID: NCT01567163 Completed - Clinical trials for Malignant Solid Tumor

A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors

Start date: July 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the effect of concomitant ramucirumab on the pharmacokinetics of docetaxel in participants with advanced malignant solid tumors. Participants who do not complete both Cycle 1, Day 1, and Cycle 2, Day 1 according to schedule will be replaced for the purpose of analysis; these participants may continue to receive study therapy. No dose reductions, delayed or missed doses are allowed during Cycles 1 and 2.

NCT ID: NCT01515306 Completed - Clinical trials for Malignant Solid Tumor

A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors

Start date: July 19, 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate whether there are no clinically significant pharmacokinetic effects of concomitant ramucirumab (IMC-1121B) on paclitaxel by investigating the pharmacokinetics (PK) of each in participants with advanced malignant solid tumors. Part A of this study will investigate the potential of concomitant ramucirumab (IMC-1121B) to affect the pharmacokinetics of paclitaxel. Part B of this study will investigate the pharmacokinetics of ramucirumab (IMC-1121B) as monotherapy.

NCT ID: NCT01457118 Completed - Clinical trials for Malignant Solid Tumor

An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies

Start date: October 2011
Phase: Phase 2
Study type: Interventional

The study objective of this open label, multicenter study is to provide access to NKTR-102 treatment to subjects previously enrolled in a NKTR-102 study who are without signs of disease progression since receiving NKTR-102. In addition the study will evaluate the safety of continued exposure to NKTR-102, observe disease status and survival status in subjects receiving NKTR-102, and evaluate the efficacy of NKTR-102 in subjects with advanced or metastatic solid tumors.

NCT ID: NCT01359982 Completed - Lymphomas Clinical Trials

Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects

DINAMIC
Start date: September 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and pharmacokinetic profile of RRx-001 for injection in subjects with advanced solid tumors or lymphomas for which there are no currently accepted curative therapies. This study will also conduct an exploratory evaluation of objective tumor response using CT or MRI.

NCT ID: NCT00836888 Completed - Clinical trials for Malignant Solid Tumor

ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in Japan

Start date: January 2009
Phase: Phase 1
Study type: Interventional

Evaluation of the safety, tolerability and pharmacokinetics (PK) of a single dose and multiple doses of ONO-4538 in Japanese patients with advanced malignant solid tumors, and exploratory evaluation of the pharmacological effect and efficacy of ONO-4538.

NCT ID: NCT00725634 Completed - Multiple Myeloma Clinical Trials

A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma

P05538
Start date: September 2008
Phase: Phase 1
Study type: Interventional

Phase 1 study to determine safety, tolerability, dose-limiting toxicities (DLTs), and recommended Phase 2 dose of AV-299 administered IV as monotherapy to patients with relapsed or refractory solid tumors, lymphoma, or multiple myeloma. The study will also determine the safety, tolerability and DLTs of AV-299 in combination with erlotinib in patients with relapsed or refractory solid tumors.

NCT ID: NCT00452413 Completed - Clinical trials for Non-Small Cell Lung Cancer

A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer

Start date: May 2007
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I: A study to see what doses of Enzastaurin and Erlotinib are best tolerated by participants with solid tumor cancer. Phase II: A study to see how long participants with non-small cell lung cancer (NSCLC) treated with Enzastaurin and Erlotinib live.